A Phase I Study of Amrubicin Combined with Carboplatin for Elderly Patients with Small-Cell Lung Cancer

The MTD of this combination was amrubicin 40 mg/m2 and carboplatin AUC 4.0, and the recommended dose for a phase II trial is a combination of amrubicin 35 mg/m2 and carboplatin AUC 4.0. We are now conducting a multicenter phase II trial of this regimen to determine the activity of this combination for elderly patients with SCLC.